Vergelijking
Elamipretide vs. Histrelin
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
736992-21-5
220810-26-4
Molecuulmassa
639.8 g/mol
1323.52 g/mol
Halfwaardetijd
geen gegevens
geen gegevens
Sequentie
D-Arg-Dmt-Lys-Phe-NH2geen gegevens
Werkingsmechanisme
Elamipretide
Elamipretide is a cell-permeable tetrapeptide with alternating aromatic and basic residues that selectively concentrates on cardiolipin — a phospholipid found almost exclusively in the inner mitochondrial membrane that is important for cristae curvature and the organisation of the respiratory-chain complexes. By binding cardiolipin, elamipretide is proposed to stabilise cristae architecture, support electron transport and ATP production, and reduce the formation of reactive oxygen species. These mechanistic models derive largely from cell and animal models and biophysical work; the extent to which they explain clinical efficacy in humans is, given the mixed trial results, a matter of ongoing research.
Histrelin
Continuous GnRH-agonist stimulation downregulates and desensitises the pituitary GnRH receptors — after the initial rise, LH, FSH and the sex hormones fall persistently.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
0
waarvan bij mensen
4
0
Geregistreerde effecten
4
2
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
1
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Elamipretide and Histrelin?
- Elamipretide is classified as "Onderzoek (overig)", while Histrelin is classified as "Onderzoek (overig)". Elamipretide: Elamipretide (SS-31, MTP-131, formerly Bendavia) is a synthetic, mitochondria-targeting tetrapeptide (sequence D-Arg-Dmt-Lys-Phe-NH2) that binds cardiolipin on the inner mitochondrial membrane and is proposed to stabilise cristae structure and support mitochondrial bioenergetics. It was investigated clinically by Stealth BioTherapeutics across several indications, including primary mitochondrial myopathy, Barth syndrome, heart failure, and dry age-related macular degeneration (geographic atrophy). The trial record is mixed, with several pivotal studies missing their primary endpoints. In September 2025 elamipretide (brand name Forzinity) received accelerated FDA approval in the United States solely for the ultra-rare Barth syndrome; for all other investigated indications it remains investigational and it is not approved as a medicine outside the United States. Histrelin: Histrelin is a nonapeptide GnRH agonist delivered as a once-yearly implant. Approved for central precocious puberty in children (Supprelin LA) and advanced prostate cancer (Vantas). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Elamipretide or Histrelin?
- The highest available evidence level is "Humane RCT" for Elamipretide and "Humane RCT" for Histrelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Elamipretide and Histrelin in Germany and the United States?
- Duitsland: Elamipretide — Niet goedgekeurd, Histrelin — Op recept. Verenigde Staten: Elamipretide — Op recept, Histrelin — Op recept. These are factual summaries with source and review date on the individual pages.